These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 32870314)

  • 1. Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis.
    Ioannou GN; Tang W; Beste LA; Tincopa MA; Su GL; Van T; Tapper EB; Singal AG; Zhu J; Waljee AK
    JAMA Netw Open; 2020 Sep; 3(9):e2015626. PubMed ID: 32870314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores.
    Ioannou GN; Beste LA; Green PK; Singal AG; Tapper EB; Waljee AK; Sterling RK; Feld JJ; Kaplan DE; Taddei TH; Berry K
    Gastroenterology; 2019 Nov; 157(5):1264-1278.e4. PubMed ID: 31356807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep learning models for predicting the survival of patients with hepatocellular carcinoma based on a surveillance, epidemiology, and end results (SEER) database analysis.
    Wang S; Shao M; Fu Y; Zhao R; Xing Y; Zhang L; Xu Y
    Sci Rep; 2024 Jun; 14(1):13232. PubMed ID: 38853169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of acknowledged hepatocellular carcinoma risk scores in high-risk hepatitis C patients with sustained virological response.
    Qiu L; Xu S; Qiu Y; Liu Y; Zhang J
    J Viral Hepat; 2023 Jun; 30(6):559-566. PubMed ID: 36890735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.
    Audureau E; Carrat F; Layese R; Cagnot C; Asselah T; Guyader D; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Chazouillères O; Mallat A; Grangé JD; Attali P; d'Alteroche L; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; Di Martino V; Sutton A; Pol S; Nahon P;
    J Hepatol; 2020 Dec; 73(6):1434-1445. PubMed ID: 32615276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    El-Serag HB; Kramer J; Duan Z; Kanwal F
    J Viral Hepat; 2016 Sep; 23(9):687-96. PubMed ID: 27040447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis.
    Aleman S; Rahbin N; Weiland O; Davidsdottir L; Hedenstierna M; Rose N; Verbaan H; Stål P; Carlsson T; Norrgren H; Ekbom A; Granath F; Hultcrantz R
    Clin Infect Dis; 2013 Jul; 57(2):230-6. PubMed ID: 23616492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The applicability of hepatocellular carcinoma risk prediction scores in a North American patient population with chronic hepatitis B infection.
    Abu-Amara M; Cerocchi O; Malhi G; Sharma S; Yim C; Shah H; Wong DK; Janssen HL; Feld JJ
    Gut; 2016 Aug; 65(8):1347-58. PubMed ID: 25934760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning algorithms outperform conventional regression models in predicting development of hepatocellular carcinoma.
    Singal AG; Mukherjee A; Elmunzer BJ; Higgins PD; Lok AS; Zhu J; Marrero JA; Waljee AK
    Am J Gastroenterol; 2013 Nov; 108(11):1723-30. PubMed ID: 24169273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
    Goodgame B; Shaheen NJ; Galanko J; El-Serag HB
    Am J Gastroenterol; 2003 Nov; 98(11):2535-42. PubMed ID: 14638360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
    Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C.
    Hedenstierna M; Nangarhari A; Weiland O; Aleman S
    Clin Infect Dis; 2016 Sep; 63(6):723-9. PubMed ID: 27282709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
    Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
    J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
    Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
    Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.